PHA121 oral solution / Pharvaris - LARVOL DELTA

On-Demand Program: RAPIDe-2 Extension Study (GlobeNewswire) - P2/3 | N=140 | RAPIDe-2 (NCT05396105) | Sponsor: Pharvaris Netherlands B.V. | "The analysis...showed that deucrictibant was generally well-tolerated with no safety signals observed. The data set includes a total of 337 attacks, seven of which met the definition of an upper airway, including laryngeal, attack. Of these upper airway attacks, the time to onset of symptom relief, as measured by the Patient Global Impression of Change (PGI-C), was 0.9 hours (N=7) and was consistent with that of non-airway attacks (1.1 hours, N=328). The majority of upper airway attacks were treated with a single dose of deucrictibant (85.7%), which was similar to that of non-airway attacks treated with a with a single dose of deucrictibant (85.4%)."

P2/3 data • Hereditary Angioedema

Prophylactic Program: CHAPTER-1 Open-Label Extension (OLE) (GlobeNewswire) - P2 | N=34 | HAE CHAPTER-1 (NCT05047185) | Sponsor: Pharvaris Netherlands B.V. | "The maximum exposure to deucrictibant based on available study data at the time of data cutoff was 20.8 months in the OLE, and 23.7 months in the entire study. Deucrictibant was well-tolerated with no safety signals. Ongoing treatment with deucrictibant resulted in sustained protection from HAE attacks, including total monthly attack rate, 'moderate and severe' attack rate, and rate of attacks treated with on-demand medication remaining low during OLE...at the time of data cut-off the median proportion of days with symptoms in deucrictibant-treated participants in the OLE was zero each month after a mean treatment duration of 12.8 months...HRQoL was improved at week 12 and as well as at week 62 compared to study baseline in participants treated with deucrictibant."

P2 data • Hereditary Angioedema